TABLE 1.
Demographic, clinical, and pathologic factors of the 315 patients meeting study criteria by nodal pCR
| Residual nodal disease (ypN+) (N = 237) | Nodal pCR (ypN0) (N = 78) | Total (N = 315) | p value | |
|---|---|---|---|---|
| Age, years | 0.03 | |||
| Median (range) | 51 (22–79) | 48 (29–69) | 50 (22–79) | |
| Age category, n (%) | 0.004 | |||
| < 50 years | 107 (45.1%) | 50 (64.1%) | 157 (49.8%) | |
| ≥ 50 years | 130 (54.9%) | 28 (35.9%) | 158 (50.2%) | |
| Sex, n (%) | 0.73 | |||
| Female | 235 (99.2%) | 77 (98.7%) | 312 (99.0%) | |
| Male | 2 (0.8%) | 1 (1.3%) | 3 (1.0%) | |
| Race, n (%) | 0.22 | |||
| White | 212 (89.5%) | 66 (84.6%) | 278 (88.3%) | |
| Black or African American | 4 (1.7%) | 3 (3.8%) | 7 (2.2%) | |
| Asian | 9 (3.8%) | 1 (1.3%) | 10 (3.2%) | |
| American Indian or Alaska Native | 1 (0.4%) | 1 (1.3%) | 2 (0.6%) | |
| Native Hawaiian or Pacific Islander | 1 (0.4%) | 0 | 1 (0.3%) | |
| Unknown/unreported | 10 (4.2%) | 7 (9.0%) | 17 (5.4%) | |
| Ethnicity, n (%) | 0.42 | |||
| Not Hispanic or Latino | 224 (94.5%) | 71 (91.0%) | 295 (93.7%) | |
| Hispanic or Latino | 7 (3.0%) | 3 (3.8%) | 10 (3.2%) | |
| Unknown/unreported | 6 (2.5%) | 4 (5.1%) | 10 (3.2%) | |
| Clinical T category, n (%) | 0.16 | |||
| cT0 | 4 (1.7%) | 1 (1.3%) | 5 (1.6%) | |
| cT1 | 24 (10.1%) | 12 (15.4%) | 36 (11.4%) | |
| cT2 | 92 (38.8%) | 35 (44.9%) | 127 (40.3%) | |
| cT3 | 90 (38.0%) | 22 (28.2%) | 112 (35.6%) | |
| cT4 | 27 (11.4%) | 8 (10.3%) | 35 (11.1%) | |
| Clinical N category, n (%) | 0.30 | |||
| cN1 | 214 (90.3%) | 67 (85.9%) | 281 (89.2%) | |
| cN2 | 6 (2.5%) | 3 (3.8%) | 9 (2.9%) | |
| cN3 | 17 (7.2%) | 8 (10.3%) | 25 (7.9%) | |
| Grade, n (%) | < 0.001 | |||
| Missing | 1 | 1 | 2 | |
| I (well differentiated) | 16 (6.8%) | 1 (1.3%) | 17 (5.4%) | |
| II (moderately differentiated) | 146 (61.9%) | 32 (41.6%) | 178 (56.9%) | |
| III (poorly differentiated) | 74 (31.4%) | 44 (57.1%) | 118 (37.7%) | |
| Multifocal or multicentric, n (%) | 0.01 | |||
| No | 123 (51.9%) | 53 (67.9%) | 176 (55.9%) | |
| Yes | 114 (48.1%) | 25 (32.1%) | 139 (44.1%) | |
| Pretreatment Ki67 | < 0.001 | |||
| Missing | 53 | 26 | 79 | |
| Mean (SD) | 29.0 (19.0) | 44.6 (24.5) | 32.4 (21.3) | |
| Median (range) | 25.0 (1.0–91.6) | 40.3 (2.0–98.0) | 29.0 (1.0–98.0) | |
| Interquartile range | 15.0, 37.2 | 26.2, 67.5 | 17.0, 42.6 | |
| Estrogen receptor staining, n (%) | < 0.001 | |||
| Positive, % not specified | 2 | 2 | 4 | |
| 1–10% | 8 (3.4%) | 11 (14.5%) | 19 (6.1%) | |
| 11–50% | 9 (3.8%) | 9 (11.8%) | 18 (5.8%) | |
| 51–70% | 8 (3.4%) | 5 (6.6%) | 13 (4.2%) | |
| > 70% | 210 (89.4%) | 51 (67.1%) | 261 (83.9%) | |
| Progesterone receptor status, n (%) | <0.001 | |||
| Negative | 26 (11.0%) | 28 (35.9%) | 54 (17.1%) | |
| Positive | 211 (89.0%) | 50 (64.1%) | 261 (82.9%) | |
| Breast pCR, n (%) | <0.001 | |||
| No | 222 (93.7%) | 46 (59.0%) | 268 (85.1%) | |
| Yes | 15 (6.3%) | 32 (41.0%) | 47 (14.9%) | |
| Pathologic T category, n (%) | <0.001 | |||
| ypT0/ypTis | 15 (6.3%) | 32 (41.0%) | 47 (14.9%) | |
| ypT1 | 87 (36.7%) | 28 (35.9%) | 115 (36.5%) | |
| ypT2 | 70 (29.5%) | 15 (19.2%) | 85 (27.0%) | |
| ypT3 | 50 (21.1%) | 2 (2.6%) | 52 (16.5%) | |
| ypT4 | 15 (6.3%) | 1 (1.3%) | 16 (5.1%) | |
| Pathologic N category, n (%) | <0.001 | |||
| ypN0 | 0 (0.0%) | 78 (100.0%) | 78 (24.8%) | |
| ypN1 | 111 (46.8%) | 0 (0.0%) | 111 (35.2%) | |
| ypN2 | 81 (34.2%) | 0 (0.0%) | 81 (25.7%) | |
| ypN3 | 45 (19.0%) | 0 (0.0%) | 45 (14.3%) |